How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,208 results for

Non-Hodgkins Lymphoma

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Somatic tumour gene testing for the diagnosis of diffuse large B cell lymphoma, multiple myeloma and non-Hodgkin lymphoma subtypes

Somatic tumour gene testing for the diagnosis of diffuse large B cell lymphoma, multiple myeloma and non-Hodgkin lymphoma subtypes 1 Public Summary Document Application No. 1526 – Somatic gene testing of haematological malignancies Applicant: The Royal College of Pathologists of Australasia (RCPA) Date of MSAC consideration: MSAC 76 th Meeting, 1-2 August 2019 Context for decision: MSAC makes its advice in accordance with its Terms of Reference, visit the MSAC website 1. Purpose of application (...) abnormalities in Non-Hodgkin Lymphoma: • MYC gene rearrangement for the diagnosis of Burkitt Lymphoma, AND/OR • one or more of CCND1 and CCND2 gene rearrangements for the diagnosis of Mantle Cell Lymphoma, AND/OR • i(q7) for the diagnosis of Hepatosplenic T-cell Lymphoma (Peripheral T-cell NHL) • DUSP22 and TP63 gene rearrangements for the diagnosis of ALK negative Anaplastic Large Cell Lymphoma, AND/OR • one or more TCL1A or MTCP1 gene rearrangements in a patient with T-cell Prolymphocytic Leukaemia. Fee

2020 Medical Services Advisory Committee

2. Allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma and in T-cell non-Hodgkin lymphoma

Allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma and in T-cell non-Hodgkin lymphoma 1 Translation of Chapters 1 to 6 of the final report N17-02 Allogene Stammzelltransplantation bei aggressiven B-Zell-Non-Hodgkin-Lymphomen und bei T-Zell-Non-Hodgkin-Lymphomen (Version 1.0; Status: 26 March 2019 [German original], 19 November 2019 [English translation]). Please note: This document was translated by an external translator and is provided as a service by IQWiG (...) to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. N17-02 Allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma and in T-cell non- Hodgkin lymphoma 1 Extract of final report N17-02 Version 1.0 Allogeneic stem cell transplantation in aggressive B-NHL and T-NHL 26 March 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

3. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies

(ERG). See the committee papers for full details of the evidence. Potential new treatment option There is an unmet need for more effectiv There is an unmet need for more effective treatment options e treatment options 3.1 Diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma are aggressive subtypes of non-Hodgkin lymphoma. Outcomes for people with refractory or relapsed disease are poor. The condition does not respond well to treatment, and survival is limited. A patient (...) Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies Axicabtagene ciloleucel for treating Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and diffuse large B-cell lymphoma and primary mediastinal large B-cell primary mediastinal large B-cell lymphoma after 2 or more systemic lymphoma after 2 or more systemic ther therapies apies T echnology appraisal guidance Published: 23 January

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

4. Rituximab (Blitzima) - follicular lymphoma and diffuse large B cell non-Hodgkin?s lymphoma OR chronic lymphocytic leukaemia OR granulomatosis with polyangiitis (GPA or Wegener?s granulomatosis) and microscopic polyangiitis (MPA)

Rituximab (Blitzima) - follicular lymphoma and diffuse large B cell non-Hodgkin?s lymphoma OR chronic lymphocytic leukaemia OR granulomatosis with polyangiitis (GPA or Wegener?s granulomatosis) and microscopic polyangiitis (MPA) 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 18 May 2017 EMA/CHMP/421793/2017 Committee (...) Methotrexate NA Not available NAb Neutralising antibody NHL NonHodgkin’s lymphoma NANA NSAID N-Acetylneuraminic acid Non-steroid anti-inflammatory drugs OOS ORR Out of Specification Overall response rate PBMCs Peripheral blood mononuclear cell PD Pharmacodynamics PK Pharmacokinetics PML Progressive multifocal leukoencephalopathy PPD Pharmaceutical Product Development, LLC PRES Posterior reversible encephalopathy syndrome PT Preferred term PY Patient-year QbD RA Quality by Design Rheumatoid arthritis QTPP

2017 European Medicines Agency - EPARs

5. Rituximab (Ritemvia) - follicular lymphoma and diffuse large B cell non-Hodgkin?s lymphoma OR granulomatosis with polyangiitis (GPA or Wegener?s granulomatosis) and microscopic polyangiitis (MPA)

Rituximab (Ritemvia) - follicular lymphoma and diffuse large B cell non-Hodgkin?s lymphoma OR granulomatosis with polyangiitis (GPA or Wegener?s granulomatosis) and microscopic polyangiitis (MPA) 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 18 May 2017 EMA/CHMP/421799/2017 Committee for Medicinal Products for Human Use (CHMP (...) Not available NAb Neutralising antibody NHL NonHodgkin’s lymphoma NANA NSAID N-Acetylneuraminic acid Non-steroid anti-inflammatory drugs OOS ORR Out of Specification Overall response rate PBMCs Peripheral blood mononuclear cell PD Pharmacodynamics PK Pharmacokinetics PML Progressive multifocal leukoencephalopathy PPD Pharmaceutical Product Development, LLC PRES Posterior reversible encephalopathy syndrome PT Preferred term PY Patient-year QbD RA Quality by Design Rheumatoid arthritis QTPP RF Quality Target

2017 European Medicines Agency - EPARs

6. Rituximab (Rituzena (previously Tuxella)) - follicular lymphoma and diffuse large B cell non-Hodgkin?s lymphoma OR chronic lymphocytic leukaemia OR granulomatosis with polyangiitis (GPA or Wegener?s granulomatosis) and microscopic polyangiitis (MPA)

Rituximab (Rituzena (previously Tuxella)) - follicular lymphoma and diffuse large B cell non-Hodgkin?s lymphoma OR chronic lymphocytic leukaemia OR granulomatosis with polyangiitis (GPA or Wegener?s granulomatosis) and microscopic polyangiitis (MPA) 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 18 May 2017 EMA/CHMP/421811 (...) Neutralising antibody NHL NonHodgkin’s lymphoma NANA NSAID N-Acetylneuraminic acid Non-steroid anti-inflammatory drugs OOS ORR Out of Specification Overall response rate PBMCs Peripheral blood mononuclear cell PD Pharmacodynamics PK Pharmacokinetics PML Progressive multifocal leukoencephalopathy PPD Pharmaceutical Product Development, LLC PRES Posterior reversible encephalopathy syndrome PT Preferred term PY Patient-year QbD RA Quality by Design Rheumatoid arthritis QTPP RF Quality Target Product Profile

2017 European Medicines Agency - EPARs

7. Rituximab (Truxima) - follicular lymphoma and diffuse large B cell non-Hodgkin?s lymphoma, chronic lymphocytic leukaemia, severe rheumatoid arthritis, granulomatosis with polyangiitis

Rituximab (Truxima) - follicular lymphoma and diffuse large B cell non-Hodgkin?s lymphoma, chronic lymphocytic leukaemia, severe rheumatoid arthritis, granulomatosis with polyangiitis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 15 December 2016 EMA/CHMP/75695/2017 Committee for Medicinal Products for Human Use (CHMP (...) for Human Use Immunoglobulin IPC IRR In-process control Infusion-related reaction ITT Intent-to-treat IV Intravenous LLN Lower limit of normal LLoQ Lower limit of quantification LMW LOCF Low Molecular Weight Last observation carried forward LTBFL Low-tumour-burden follicular lymphoma MCB MoA Master cell bank Mechanism of action MPA Microscopic polyangiitis MTX Methotrexate NA Not available NAb Neutralising antibody NHL NonHodgkin’s lymphoma NANA NSAID N-Acetylneuraminic acid Non-steroid anti

2017 European Medicines Agency - EPARs

8. Axicabtagene ciloleucel (Yescarta) - diffuse large B-cell lymphoma (DLBCL); primary mediastinal large B-cell lymphoma (PMBCL)

showed that higher levels (peak and AUC at 1 month) of IL-15, as well as IL-6, were associated with Grade 3 or higher neurologic adverse reactions and Grade 3 or higher CRS. Clinical efficacy and safety DLBCL, PMBCL and DLBCL arising from follicular lymphoma (ZUMA-1) A total of 108 patients were treated with YESCARTA in a phase 1/2 open-label, multicenter, single- arm study in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). Efficacy was based on 101 patients (...) Axicabtagene ciloleucel (Yescarta) - diffuse large B-cell lymphoma (DLBCL); primary mediastinal large B-cell lymphoma (PMBCL) 1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT YESCARTA 0.4 – 2 x 10 8 cells

2018 European Medicines Agency - EPARs

9. Non-Hodgkin's lymphoma

Non-Hodgkin's lymphoma Non-Hodgkin's lymphoma - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Search Select language Non-Hodgkin's lymphoma Last reviewed: December 2019 Last updated: March 2019 Summary Clinical history depends on the type of lymphoma and stage at presentation. Diagnosis is confirmed by tissue (e.g., lymph node, bone marrow, blood, skin) sampling. Diffuse large B-cell lymphoma is the most common type (...) of lymphoma. Treatment is based on the histological subtype and severity of symptoms at presentation. R-CHOP-21 (rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisolone given for 21 days) is the most commonly used chemotherapy regimen. Definition Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of malignancies of the lymphoid system. Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med. 1993 Apr 8;328(14):1023-30. http://www.ncbi.nlm.nih.gov/pubmed/8450856?tool

2019 BMJ Best Practice

10. Rituximab (Truxima) - Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia or Rheumatoid Arthritis

Rituximab (Truxima) - Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia or Rheumatoid Arthritis Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity

2019 Health Canada - Drug and Health Product Register

11. Axicabtagene ciloleucel (Yescarta) - relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL)

are expanded and infused back into the patient, where they can recognise and eliminate CD19 expressing target cells. 1-3 Axicabtagene ciloleucel for use in diffuse large B cell lymphoma (DLBCL) has been considered by SMC using its decision-making framework for the assessment of ultra-orphan medicines. Nature of condition DLBCL is an aggressive form of non-Hodgkin’s lymphoma (NHL) and represents 30% and 58% of NHL cases. 4 Most DLBCLs begin in lymph nodes but up to 40% may originate in extranodal sites (...) Axicabtagene ciloleucel (Yescarta) - relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL) Published 07 October 2019 1 SMC2189 axicabtagene ciloleucel 0.4 – 2 x 10 8 cells dispersion for infusion dispersion for infusion (Yescarta®) Kite Pharma, a Gilead Company 06 September 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees

2019 Scottish Medicines Consortium

12. Axicabtagene ciloleucel (Yescarta) - Treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL)

transduction to express the anti-CD19 chimeric antigen receptor (CAR). Anti- CD19 CAR-positive viable T cells are expanded and infused back into the patient, where they can recognise and eliminate CD19 expressing target cells. 1-3 Axicabtagene ciloleucel for use in diffuse large B cell lymphoma (DLBCL) has been considered by SMC using its decision-making framework for the assessment of ultra-orphan medicines. Nature of condition DLBCL is an aggressive form of non-Hodgkin’s lymphoma (NHL) and represents 30 (...) Axicabtagene ciloleucel (Yescarta) - Treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL) Published 11 February 2019 1 SMC2114 axicabtagene ciloleucel 0.4 – 2 x 10 8 cells dispersion for infusion dispersion for infusion (Yescarta®) Kite Pharma, a Gilead Company 9 November 2018 (issued 11 January 2019) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises

2019 Scottish Medicines Consortium

13. British Association of Dermatologists and U.K. Curaneous Lymphoma Group (CLG) guidelines for the management of primary cutaneous lymphomas

recommendations. All subsections were subsequently collated, circulated within the GDG and edited toproducethe?nalguideline. 3.0 Introduction 3.1. Incidence and epidemiology Primary cutaneous lymphomas represent a heterogeneous group of extranodal non-Hodgkin lymphomas, consisting of cutaneous B-cell lymphoma (CBCL) and cutaneous T-cell lym- phoma (CTCL). CTCL represents around 70% and CBCL about 30% of primary cutaneous lymphomas. Primary cutaneous lymphomas have been de?ned by the European Organisation (...) of erythrodermic disease. It can also be useful for treating extensive involvement of the hands and feet. 6.1.4.4 Stage IVA2–B mycosis fungoides/S ezary syndrome Localized, peripheral nodal disease can be treated with local external beam radiotherapy, as per standard protocols for non- Hodgkin lymphoma. Visceral metastases can also be treated with external beam radiotherapy using the same dosing sched- ules. Relatively low doses or single fractions can provide effec- tive palliation and should be considered

2019 British Association of Dermatologists

14. Non-Hodgkin's lymphoma

Non-Hodgkin's lymphoma Non-Hodgkin's lymphoma - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Non-Hodgkin's lymphoma Last reviewed: February 2019 Last updated: March 2019 Important updates 15 Mar 2019 FDA issues alert over link between breast implants and anaplastic large cell lymphoma The US Food and Drug Administration (FDA) has issued a letter to alert healthcare providers to the increased risk of anaplastic large (...) of lymphoma. Treatment is based on the histological subtype and severity of symptoms at presentation. R-CHOP-21 (rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisolone given for 21 days) is the most commonly used chemotherapy regimen. Definition Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of malignancies of the lymphoid system. Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med. 1993 Apr 8;328(14):1023-30. http://www.ncbi.nlm.nih.gov/pubmed/8450856?tool

2018 BMJ Best Practice

15. Mogamulizumab-kpkc (Poteligeo) - To treat two rare types of non-Hodgkin lymphoma

Mogamulizumab-kpkc (Poteligeo) - To treat two rare types of non-Hodgkin lymphoma Drug Approval Package: Poteligeo (mogamulizumab-kpkc) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Poteligeo (mogamulizumab-kpkc) Company: Kyowa Kirin, Inc. Application Number: 761051 Approval Date: 08/08/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA

2018 FDA - Drug Approval Package

17. Idelalisib for treating refractory follicular lymphoma

of autologous stem cell transplantation after idelalisib or chemother ansplantation after idelalisib or chemotherap apy y should be considered should be considered 3.4 The clinical experts stated that response to second-line treatment is consolidated with autologous stem cell transplantation in people who are considered fit enough, in line with NICE's guideline on non-Hodgkin's lymphoma: diagnosis and management. They also noted that, if a patient was healthy, autologous stem cell transplantation would (...) for the committee to consider There are no mapped utilities for the committee to consider 3.20 The company submitted utility values to reflect health-related quality of life from a published study (Wild et al. 2006), even though it had collected quality- of-life data in DELTA. The ERG submitted scenario analyses with alternative utility values from other published studies (Bec et al. 2014 and the GADOLIN trial for non-Hodgkin's indolent lymphoma). The clinical experts agreed that all values seemed reasonable

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

18. Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma

(CTCL) is a form of non-Hodgkin lymphoma that affects the skin. It may start as flat red patches or plaques on the surface of the skin, which progress to skin tumours. People may also have systemic symptoms, such as chronic pain and itching, that can severely limit daily activities. The clinical experts explained that CTCL is a rare disease and people usually live with their condition for many years. The patient experts explained that being diagnosed with CTCL can severely affect a person's physical (...) and their families and carers. The committee concluded that CTCL significantly reduces patients' quality of life. There is an unmet need for more effectiv There is an unmet need for more effective treatment options e treatment options 3.2 There is no NICE guidance on treating CTCL. The disease can be divided into a number of subtypes, only some of which express the tumour marker CD30. CD30 is expressed in both primary cutaneous anaplastic large cell lymphoma and lymphomatoid papulosis, which together form

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

19. Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies

There is an unmet need for more effectiv There is an unmet need for more effective treatment options e treatment options 3.1 Diffuse large B-cell lymphoma is an aggressive subtype of non-Hodgkin lymphoma. Outcomes for people with refractory or relapsed disease are poor. The disease has low levels of response to treatment, and is associated with limited survival. A patient expert explained that in a survey of over 100 people with the disease, the most commonly reported side effects of treatment included fatigue (...) rituximab). The clinical experts also advised that Gem-Ox with or without rituximab is more likely to be used with palliative intent. The committee noted that the company had included pixantrone monotherapy as a comparator for some people in line with NICE's technology appraisal guidance on pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma. The clinical experts explained that pixantrone is rarely used in clinical practice, has poor efficacy

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

20. Rituximab for Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Details

Rituximab for Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Details Rituximab for Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Details | CADTH.ca Find the information you need Rituximab for Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Details Rituximab for Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Details Project Number pCODR 10180 Brand Name TBD Generic Name Rituximab Strength Tumour Type Lymphoma & Leukemia Indication Non-Hodgkin’s (...) Lymphoma and Chronic Lymphocytic Leukemia Biosimilar Funding Request Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia Review Status File-Closed Not Submitted Clarification The submitter notified pCODR that they will not be filing the submission. Pre Noc Submission Yes NOC Date Manufacturer Sandoz Canada Sponsor Sandoz Canada Submission Date (Target Date) Submission Deemed Complete Submission Type Biosimilar – New Drug Stakeholder Input Deadline (target date based on target submission date

2019 CADTH - Pan Canadian Oncology Drug Review

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>